Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 51 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BELGIAN DIAGNOSTIC COMPANY from Marche-en-Famenne, company number BE0432680178, closed financial year 2025 with a result of € 296,342 after tax. For that financial year BELGIAN DIAGNOSTIC COMPANY recorded revenue of € 17.7 million and equity of € 1.9 million. Compared with financial year 2024, the result moved from € 951,854 to € 296,342. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 1.9 million
▲ 18% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 296,342
▼ 69% vs 2024
Profit after tax over the fiscal year.
€ 251,118
▼ 8% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 7,903.
People and assets in 2025
134.4
▲ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 7 million
€ 52,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2.3 million
▼ 5% vs 2024
Of which on lease € 2.2 million.
Debts at end 2025
€ 4.1 million
▼ 11% vs 2024
€ 689,411 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 1.3 million
▼ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 51 days on average.
€ 1.2 million
▲ 20% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 15,896,939 | € 16,388,567 | € 18,381,099 | € 17,680,223 | ▼ 4% |
| Profit after taxes | € -733,346 | € 241,511 | € 951,854 | € 296,342 | ▼ 69% |
| Equity | € 427,493 | € 648,029 | € 1,580,451 | € 1,858,005 | ▲ 18% |
| Total debts | € 8,055,071 | € 7,484,124 | € 7,119,847 | € 6,632,015 | ▼ 7% |
| Cash | € 83,331 | € 425,150 | € 273,156 | € 251,118 | ▼ 8% |
| Land & buildings | € 1,309,544 | € 1,215,982 | € 1,161,513 | € 1,009,079 | ▼ 13% |
| Retained profit | € -1,481,804 | € -1,240,293 | € -288,439 | € 7,903 | ▲ € 296,342 |
| Bank debt | € 5,016,610 | € 5,152,308 | € 4,656,299 | € 4,147,915 | ▼ 11% |
| Balance sheet total | € 8,484,598 | € 8,133,061 | € 8,700,875 | € 8,490,597 | ▼ 2% |
| Employees (FTE) | 117 | 129 | 134 | 134.4 | ▲ 0.4 |
Key figures of BELGIAN DIAGNOSTIC COMPANY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BELGIAN DIAGNOSTIC COMPANY?
What happened at BELGIAN DIAGNOSTIC COMPANY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jessica Wève stepped down as director. NBB
- NATALIS DEVELOPPEMENT SAS 991259714 stepped down as director. NBB
- MB SOLUTIONS srl SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 296,342 (▼ 69% vs 2024). Source: NBB ↗
- Jessica Wève became a director. NBB
- NATALIS DEVELOPPEMENT SAS 991259714 became a director. NBB
- MB SOLUTIONS srl SRL became a director. NBB
- New establishment in Marche-en-Famenne. KBO
In short
From € 733,346 loss in 2022 to € 296,342 profit in 2025.
Paid € 22,820 in corporate taxes since 2022.
Best year ever: 2024, with € 951,854 profit.
Pays suppliers within 51 days on average.
A new publication or filing at BELGIAN DIAGNOSTIC COMPANY? We notify you, reason included.
Follow BELGIAN DIAGNOSTIC COMPANYDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by INTERNATIONAL MEDICAL PRODUCTS (54%) and MEDIPREMA GROUP (46%). It owns 50% of BELDICO FRANCE SAS itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2031
NATALIS DEVELOPPEMENT SAS 991259714
Managing director · represented by Vincent Camus
since 2025 · until 2031
Director · represented by Marc Bemelmans
Also active at: INTERNATIONAL MEDICAL PRODUCTS
since 2025 · until 2031
Shareholders
MEDIPREMA GROUP
46%
Participations
BELDICO FRANCE SAS
50%
Establishments
Establishment units
Physical locations of this company
Aye, Rue André Feher 3
6900 Marche-en-Famenne
Aye, Rue André Feher 1
6900 Marche-en-Famenne
Active since 23 December 1987
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0432.680.178
- VAT number
- BE 0432.680.178
- Registered office
- Aye, Rue André Feher 3, 6900 Marche-en-Famenne
- Names & denominations
- BELGIAN DIAGNOSTIC COMPANY · BELDICO
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 November 1987
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde
Vervaardiging van farmaceutische grondstoffen